Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?

Bartolome Burguera; Khawla F Ali; Juan P Brito

doi:10.3949/ccjm.84.s1.05

Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?

Cleve Clin J Med. 2017 Jul;84(7 Suppl 1):S39-S46. doi: 10.3949/ccjm.84.s1.05.

Authors

Bartolome Burguera^{1

2

3}, Khawla F Ali⁴, Juan P Brito^{5

6}

Affiliations

¹ Director of Obesity Programs, Endocrinology & Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA. burgueb@ccf.org.
² Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
³ Medical Director, National Diabetes and Obesity Research Institute, Tradition, MS, USA.
⁴ Endocrinology & Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Division of Endocrinology, Assistant Professor of Medicine, Medical Director of the Shared Decision Making National Resource Center Investigator, Knowledge and Evaluation Research Unit, Mayo Clinc, Rochester, MN, USA.
⁶ Department of Medicine, Mayo Clinic, Rochester, MN, USA.

PMID: 28708481
DOI: 10.3949/ccjm.84.s1.05

Abstract

Antiobesity medications can improve metabolic control for patients with type 2 diabetes mellitus (DM) and obesity, but are underutilized. In this review, we describe the role of antiobesity drugs in the context of medically supervised and comprehensive weight-loss interventions and propose a pragmatic therapeutic algorithm for patients with type 2 DM and obesity that incorporates the use of antiobesity drugs early in the course of management.

Publication types

Review

MeSH terms

Adult
Anti-Obesity Agents / therapeutic use*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Female
Humans
Male
Obesity / complications
Obesity / drug therapy*
Weight Loss / drug effects
Weight Reduction Programs / methods

Substances

Anti-Obesity Agents